#ACC16: HOPE-3 Study. 100 intermediate-risk persons would have to be treated with statins for 5 years to prevent 1 cardiovascular event

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease – New England Journal of Medicine (free)

Editorial: More HOPE for Prevention with Statins – New England Journal of Medicine (free)

HOPE-3: Does Primary Cardiovascular Prevention Benefit People at Intermediate Risk? – NEJM Journal Watch commentary (free)

Statin treatment reduced cardiovascular events more than hypertension drugs in intermediate-risk patients, study finds – ACP Internist Weekly Review (free)

HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients – Medscape commentary (free registration required)